Nephrogen vs Hims & Hers
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 preclinical gene therapy for polycystic kidney disease (600K US patients) using AI-driven target identification; $1.1M raised with NIH SBIR grant, raising $4M seed competing with CRISPR Therapeutics for curative kidney genetic medicine.
About
Nephrogen is a San Francisco-based preclinical gene therapy company — backed by Y Combinator (W20) with $1.1 million in total funding including $775,000 raised to date plus a $325,000 NIH SBIR grant, and currently raising a $4 million seed round with support from StartX and 2048 Ventures — developing curative gene therapies for kidney diseases, with polycystic kidney disease (PKD) as the lead program targeting the 600,000 Americans with the autosomal dominant PKD subtype, an inherited kidney cyst disorder with no disease-modifying treatments that currently progresses to end-stage renal disease requiring dialysis or transplant in the majority of patients. Founded by researchers with combined expertise in AI-driven drug discovery, genetic engineering, and nephrology, Nephrogen applies AI target identification and gene therapy delivery to the largest category of rare inherited kidney diseases.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
About
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.